4 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 NEWS CordenPharma Colorado partners with BioMed Realty on peptide development lab expansion at Flatiron Park in Boulder BioMed Realty, the largest private owner and operator of real estate for the life science, technology and innovation industries, announced that CordenPharma Colorado, a leading peptide drug substance Contract Development and Manufacturing Organization (CDMO), has leased 64,000 square feet at Flatiron Park’s 5505 Central – Boulder’s first purpose-built speculative lab building – near the existing CordenPharma Colorado facility. Flatiron Park is BioMed Realty’s premier Boulder campus, supporting life science, quantum and technology tenants through highly resilient infrastructure, flexible building solutions, and a thoughtfully curated campus environment. CordenPharma Colorado’s 15-year lease reinforces Flatiron Park’s position as a critical hub for innovation, and validates BioMed Realty’s substantial, longterm investment in the Boulder innovation ecosystem. CordenPharma Colorado will be the sole tenant at 5505 Central. The new LEED® Gold-certified facility features robust power capacity, adaptable lab grids, advanced mechanical and utility systems, and efficient waste disposal to support complex scientific operations. Strategically located adjacent to CordenPharma Colorado’s large-scale peptide manufacturing facility, the space will house process development and analytical services, enabling seamless integration of advanced peptide Active Pharmaceutical Ingredient (API) production from development through commercialization. Beyond Colorado, the expanded peptide development capabilities Picture. (CordenPharma Photo) CordenPharma Colorado is leasing 5505 Central, a newly completed, purpose-built peptide development lab at Flatiron Park in Boulder, CO (US). - CordenPharma Colorado expands its leadership in complex peptide development with the lease of a new 64,000 sq. ft. LEED® Gold-certified facility in Boulder, Colorado (US), strengthening its position as a premier global CDMO delivering advanced peptide APIs from early development through commercialization. - The new process development and analytical labs enable seamless scale‑up from early development to full commercial peptide API manufacturing, leveraging the proximity of CordenPharma’s nearby large‑scale facility. - The expanded peptide development capabilities will be fully integrated into CordenPharma’s growing global facility network, enabling pharma and biotech partners access to end‑to‑end peptide drug substance and drug product supply chain, including First-in-Human clinical trial peptide production, extensive sterile injectable drug product capacity and advanced oral solid peptide delivery services. - CordenPharma Colorado is growing its team to support this expansion, inviting scientists and specialists to explore open roles and join a world‑class peptide development organization. Visit cordenpharma.com for more information. created at this location will be integrated into CordenPharma’s growing global network across Europe and the U.S. “We’re excited to partner with BioMed Realty on this project to accelerate our strategic growth and meet customer demand for complex peptide outsourcing, while creating additional jobs and attracting research talent to the region,” said Michael Landau, Managing Director of CordenPharma Colorado. “With our strong team and strategic vision, backed by our global facility network, these new labs will grow the life sciences sector in Boulder. As a CDMO, our Development Laboratories are foundational in delivering effective support to customers and their patients.”
RkJQdWJsaXNoZXIy MjY2OTA4MA==